Sirolimus-FKBP12.6 impairs endothelial barrier function through protein kinase C-α activation and disruption of the p120-vascular endothelial cadherin interaction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 10, 2013, Pages 2425-2431

  Habib, Anwer ^a   Karmali, Vinit ^a   Polavarapu, Rohini ^a   Akahori, Hirokuni ^a   Cheng, Qi ^b   Pachura, Kim ^a   Kolodgie, Frank D ^b   Finn, Aloke V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CVPATH INSTITUTE   (United States)

Author keywords

endothelium; PKC ; sirolimus

Indexed keywords

CATENIN; FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE C ALPHA; PROTEIN P120; RAPAMYCIN; RYANODINE; RYANODINE RECEPTOR; SMALL INTERFERING RNA; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL PERMEABILITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; CYTOSOL; ELECTRIC RESISTANCE; ENDOTHELIAL BARRIER FUNCTION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; EXTRAVASATION; GAP JUNCTION; HEART; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUNG; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ENDOTHELIUM; PKC; SIROLIMUS;

ANIMALS; ANTIGENS, CD; CADHERINS; CALCIUM SIGNALING; CAPILLARY PERMEABILITY; CATENINS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C-ALPHA; RNA INTERFERENCE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS BINDING PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 84885030203     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301659     Document Type: Article

References (36)

1. van Nieuw Amerongen GP, Vermeer MA, Nègre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh VW. Simvastatin improves disturbed endothelial barrier function. Circulation. 2000;102:2803-2809
2. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev. 2006;86:279-367
3. Gonzalez-Vilchez F, Vazquez de Prada JA, Almenar L, et al. Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation. J Heart Lung Transplant. 2012;31:288-295
4. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314-1322
5. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: A final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051-2057
6. Oroszlán M, Bieri M, Ligeti N, Farkas A, Koestner SC, Meier B, Mohacsi PJ. Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant. J Heart Lung Transplant. 2008;27:1311-1318
7. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159-170
8. Long C, Cook LG, Wu GY, Mitchell BM. Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2007;27:1580-1586
9. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasová E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell. 1994;77:513-523
10. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990;87:9231-9235
11. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42
12. Timerman AP, Onoue H, Xin HB, Barg S, Copello J, Wiederrecht G, Fleischer S. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem. 1996;271:20385-20391
13. Long C, Cook LG, Hamilton SL, Wu GY, Mitchell BM. FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension. 2007;49:569-576
14. Hempel A, Lindschau C, Maasch C, Mahn M, Bychkov R, Noll T, Luft FC, Haller H. Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. Circulation. 1999;99:2523-2529
15. Sandoval R, Malik AB, Minshall RD, Kouklis P, Ellis CA, Tiruppathi C. Ca(2+) signalling and PKCalpha activate increased endothelial permeability by disassembly of VE-cadherin junctions. J Physiol. 2001;533(pt 2):433-445
16. Lynch JJ, Ferro TJ, Blumenstock FA, Brockenauer AM, Malik AB. Increased endothelial albumin permeability mediated by protein kinase C activation. J Clin Invest. 1990;85:1991-1998
17. Parekh DB, Ziegler W, Parker PJ. Multiple pathways control protein kinase C phosphorylation. EMBO J. 2000;19:496-503
18. Vandenbroucke St Amant E, Tauseef M, Vogel SM, Gao XP, Mehta D, Komarova YA, Malik AB. Pkcalpha activation of p120-catenin serine 879 phospho-switch disassembles VE-cadherin junctions and disrupts vascular integrity. Cir Res. 2012;111:739-749
19. Iyer S, Ferreri DM, DeCocco NC, Minnear FL, Vincent PA. VE-cadherin-p120 interaction is required for maintenance of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1143-L1153
20. Liu Q, Xu C, Kirubakaran S, et al. Characterization of torin2, an atp-competitive inhibitor of mTOR, ATM and ATR. Cancer Res. 2013;73:2574-2586
21. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl) phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem. 2011;54:1473-1480
22. Habib A, Karmali V, Polavarapu R, Akahori H, Nakano M, Yazdani S, Otsuka F, Pachura K, Davis T, Narula J, Kolodgie FD, Virmani R, Finn AV. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol. 2013;61:971-980
23. Baker H, Sidorowicz A, Sehgal SN, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo). 1978;31:539-545
24. Chen BJ, Morris RE, Chao NJ. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms. Biol Blood Marrow Transplant. 2000;6(5A):529-536
25. Mukai Y, Rikitake Y, Shiojima I, Wolfrum S, Satoh M, Takeshita K, Hiroi Y, Salomone S, Kim HH, Benjamin LE, Walsh K, Liao JK. Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest. 2006;116:334-343
26. Phung TL, Eyiah-Mensah G, O'Donnell RK, Bieniek R, Shechter S, Walsh K, Kuperwasser C, Benjamin LE. Endothelial Akt signaling is ratelimiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res. 2007;67:5070-5075
27. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250
28. Xiao K, Allison DF, Buckley KM, Kottke MD, Vincent PA, Faundez V, Kowalczyk AP. Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells. J Cell Biol. 2003;163:535-545
29. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106:1319-1331
30. Rigor RR, Shen Q, Pivetti CD, Wu MH, Yuan SY. Myosin light chain kinase signaling in endothelial barrier dysfunction. Med Res Rev. August 9, 2012. doi: 10.1002/med.21270. http://onlinelibrary.wiley. com/doi/10.1002/med.21270/ abstract;jsessionid=FCB134312B4D748 EA69167C51FA75EEB.d02t04. Accessed July 30, 2013
31. Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol. 2010;72:463-493
32. Satpathy M, Gallagher P, Lizotte-Waniewski M, Srinivas SP. Thrombin-induced phosphorylation of the regulatory light chain of myosin II in cultured bovine corneal endothelial cells. Exp Eye Res. 2004;79:477-486
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101
34. Vilella-Bach M, Nuzzi P, Fang Y, Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycinassociated protein kinase activity and G1 progression. J Biol Chem. 1999;274:4266-4272
35. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22:1-15
36. Moro JA, Almenar L, Martínez-Dolz L, Sánchez-Lázaro I, Agüero J, Salvador A. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc. 2008; 40:3034-3036